<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117065</url>
  </required_header>
  <id_info>
    <org_study_id>20030139</org_study_id>
    <nct_id>NCT00117065</nct_id>
  </id_info>
  <brief_title>Study of Transplant Related Anemia Treated With Aranesp® (STRATA)</brief_title>
  <official_title>Study of Transplant Related Anemia Treated With Aranesp® (STRATA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate Aranesp® administered subcutaneously (SC) to
      maintain hemoglobin (Hb) levels in renal transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin values</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF-36 summary and individual domain scores at week 24</measure>
  </secondary_outcome>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aranesp®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subjects who are greater than 6 months post-renal transplant (living
        or cadaveric) - Using adequate contraceptive precaution, if of childbearing potential -
        Available for follow-up assessments and dosing visits - Hb concentration less than 11.0
        g/dL within 3 months of screening and a hemoglobin concentration less than 11.0 during the
        screening period Exclusion Criteria: - Expected to initiate dialysis or transplantation or
        be scheduled for a kidney transplant within 6 months of study start, or have less than 1
        year life expectancy - Systemic hematologic disease, myeloma, hemolytic anemia, or
        malignancy (excluding basal cell carcinoma) - Active systemic or chronic infection -
        Uncontrolled hypertension defined as diastolic blood pressure greater than 110 mm Hg on 2
        separate occasions during the 2 weeks prior to screening - Known hypersensitivity to
        Aranesp® or any of the product's excipients - Disorders that compromise the ability of the
        subject to give written informed consent and/or to comply with study procedures - Use of
        any erythropoietic protein or androgen therapy within the 12 weeks prior to screening -
        Females who are pregnant or breast-feeding - Currently enrolled in or received treatment in
        an investigational drug/device trial within the past 30 days - Have previously been
        enrolled in this study - Recent history (within 12 weeks prior to screening) of severe
        cardiovascular events, grand mal seizure, dialysis or major surgery - Have received a red
        blood cell transfusion(s) within 8 weeks prior to screening, or currently have active
        bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.aranesp.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <results_reference>
    <citation>Bloom RD, Bolin P, Gandra SR, Scarlata D, Petersen J. Impact on health-related quality of life in kidney transplant recipients with late posttransplant anemia administered darbepoetin alfa: results from the STRATA study. Transplant Proc. 2011 Jun;43(5):1593-600. doi: 10.1016/j.transproceed.2011.02.009.</citation>
    <PMID>21693239</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2005</study_first_posted>
  <last_update_submitted>April 24, 2013</last_update_submitted>
  <last_update_submitted_qc>April 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplant, Renal transplant</keyword>
  <keyword>Aranesp®, Darbepoetin alfa</keyword>
  <keyword>Amgen, Q2W dosing, Q4W dosing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

